• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Futuremed Acquires Exclusive Canadian Rights to Innovative New Product

Posted on: Wednesday, 3 September 2008, 15:00 CDT

Futuremed Healthcare Income Fund (TSX: FMD.UN)("Futuremed" or the "Fund") announced today that it had signed an exclusive distribution agreement to market and sell in Canada an innovative new product designed to facilitate the closure of chronic ulcers. Developed by LifeWave Ltd. of Tel Aviv Israel, the patented and clinically proven Best Sore Treatment (BST) Device is a non-invasive, painless, electro therapy technology that transmits signals around chronic ulcers and acute wounds to accelerate the healing process and reduce wound closure time. Portable and easy to use, the BST Device will provide a higher quality of care to Long Term Care Residents suffering from this condition.

"We are very pleased to have acquired exclusive access to this innovative product for our nursing home customers across Canada. One of our key objectives at Futuremed is to provide the latest and best products to our customers, ensuring Canadians have access to the highest and most effective levels of care and treatment. We are excited to be adding the BST Device to our offering, and look forward to adding additional new products going forward," commented Raymond Stone, Futuremed's President and Chief Executive Officer.

About Futuremed Healthcare Income Fund

Futuremed Healthcare Income Fund, through its operating entities, is Canada's leading value-added distributor of consumable nursing home supplies and specialized furniture and equipment to the growing long-term care facilities sector. Futuremed's Trust Units trade on the Toronto Stock Exchange under the symbol FMD.UN. More information can be found at www.futuremed.ca.

Readers are cautioned that EBITDA, distributable cash and distributable cash per unit are not Generally Accepted Accounting Principles ("GAAP") measures and should not be construed as an alternative to net earnings and earnings per share determined in accordance with GAAP as an indicator of the Fund's performance. The Fund's methods of calculating these measures may differ from other issuers' methods and accordingly, they may not be comparable to measures used by other issuers.

This document may contain forward-looking statements relating to Futuremed's operations or to the environment in which it operates, which are based on the Fund's operations, estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, and/or are beyond the Fund's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in other public filings. In addition, these forward-looking statements relate to the date on which they are made. The Fund disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these risks and uncertainties can be found in regulatory filings available at www.sedar.com.

 Contacts: Futuremed Healthcare Income Fund Daniel Sacks, Chief Financial Officer (905) 761-0068 ext. 2222 Toll Free investor relations: 1-800-387-7025 (905) 761-9929 (FAX) Website: www.futuremed.ca

SOURCE: Futuremed Healthcare Income Fund

Source: MARKET WIRE

More News in this Category